KAPA · Categories · Form 4
KAPA - SEC Form 4 insider transactions
Kairos Pharma Ltd. (KAPA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for KAPA
- Chief Scientific Officer Bhowmick Neil was granted 171,756 shares, increasing direct ownership by 15% to 1,311,739 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- Director Bae Hyun W. was granted 29,084 shares, increasing direct ownership by 66% to 73,370 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- VP of Research and Development Murali Ramachandran was granted 152,672 shares, increasing direct ownership by 104% to 299,529 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- Director Keyoung Hansoo Michael was granted 29,084 shares (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- Director Singhvi Rahul was granted 19,084 shares, increasing direct ownership by 63% to 49,204 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- CEO and Chairman Yu John S was granted 190,840 shares, increasing direct ownership by 486% to 230,105 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- Chief Financial Officer Samuelson Doug was granted 152,672 shares, increasing direct ownership by 109% to 293,039 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- Chief Scientific Officer Bhowmick Neil was granted 14,000 shares, increasing direct ownership by 1% to 1,139,983 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- VP of Research and Development Murali Ramachandran was granted 14,000 shares, increasing direct ownership by 11% to 147,057 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- CEO and Chairman Yu John S was granted 14,000 shares, increasing direct ownership by 0.26% to 5,355,838 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)